TODD STRATEGY GROUP

Lobbying for BRISTOL-MYERS SQUIBB COMPANY · Biopharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $80,000.00 income · posted Jul 20, 2026

Lobbying activity 2

Health Issues

Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.

Medicare/Medicaid

Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.